We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
-2.91%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$30M
Cap. Flow
-$21.6M
Cap. Flow %
-15.92%
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45

Top Buys

Rank Stock Value
1
ENOV icon
Enovis
ENOV
+$1.04M
2
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$1.04M
3
QQQ icon
Invesco QQQ Trust
QQQ
+$958K
4
QQQM icon
Invesco NASDAQ 100 ETF
QQQM
+$955K
5
SRPT icon
Sarepta Therapeutics
SRPT
+$929K

Top Sells

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$2.16M
2
CORT icon
Corcept Therapeutics
CORT
+$2.14M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$2.13M
4
KALV
KalVista Pharmaceuticals
KALV
+$1.49M
5
CATX icon
Perspective Therapeutics
CATX
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 60.25%
2 Real Estate 12.98%
3 Financials 6.42%
4 Industrials 2.59%
5 Technology 2.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRWD icon
201
CrowdStrike
CRWD
$202B
$38.7K 0.03%
+404
New +$33.6K
WWD icon
202
Woodward
WWD
$23.3B
$37.5K 0.03%
+215
New +$36.6K
ECH icon
203
iShares MSCI Chile ETF
ECH
$1.01B
$37.4K 0.03%
+1,445
New +$39.6K
HWM icon
204
Howmet Aerospace
HWM
$109B
$36.3K 0.03%
+468
New +$35.4K
DASH icon
205
DoorDash
DASH
$82.4B
$36K 0.03%
331
+4
+1% +$482
DDOG icon
206
Datadog
DDOG
$93.7B
$35.5K 0.03%
274
+3
+1% +$363
HUBS icon
207
HubSpot
HUBS
$11.8B
$35.4K 0.03%
60
– –
MELI icon
208
Mercado Libre
MELI
$92.9B
$34.5K 0.03%
21
-56
-73% -$88.4K
CGON icon
209
CG Oncology
CGON
$6.19B
$31.6K 0.02%
1,000
– –
KALV
210
DELISTED
KalVista Pharmaceuticals
KALV
$29.4K 0.02%
2,500
-127,500
-98% -$1.49M
ZS icon
211
Zscaler
ZS
$24.2B
$29.2K 0.02%
152
+2
+1% +$356
VTYX
212
DELISTED
Ventyx Biosciences
VTYX
$23.1K 0.02%
10,000
– –
SNOW icon
213
Snowflake
SNOW
$95.1B
$22.8K 0.02%
169
-202
-54% -$29.8K
AAL icon
214
American Airlines Group
AAL
$10B
– –
-10,404
Closed -$160K
ALNT icon
215
Allient
ALNT
$1.47B
– –
-25,000
Closed -$892K
APO icon
216
Apollo Global Management
APO
$68.2B
– –
-975
Closed -$110K
AZO icon
217
AutoZone
AZO
$48.9B
– –
-72
Closed -$227K
BSX icon
218
Boston Scientific
BSX
$65.1B
– –
-3,337
Closed -$229K
BWA icon
219
BorgWarner
BWA
$12.6B
– –
-1,742
Closed -$60.5K
CFLT
220
DELISTED
Confluent
CFLT
– –
-1,000
Closed -$30.5K
CI icon
221
Cigna
CI
$75.1B
– –
-328
Closed -$119K
COOP
222
DELISTED
Mr. Cooper
COOP
– –
-4,931
Closed -$384K
CORT icon
223
Corcept Therapeutics
CORT
$9.83B
– –
-85,000
Closed -$2.14M
CPNG icon
224
Coupang
CPNG
$29.5B
– –
-4,337
Closed -$77.2K
EIDO icon
225
iShares MSCI Indonesia ETF
EIDO
$486M
– –
-3,951
Closed -$89K
7 8
9
10 11

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, AlphaCentric Advisors held 262 positions worth $136M, down 18% from $166M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

AlphaCentric Advisors withdrew a net $21.6M in Q2 2024, closing 45 positions and reducing 87 holdings. Its most notable exit was UroGen Pharma, an estimated $2.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Enovis worth $904K.

  • AlphaCentric Advisors's largest Q2 2024 buy was Enovis: 20,000 shares worth $904K.
  • AlphaCentric Advisors added most to Invesco QQQ Trust in Q2 2024, an estimated $958K increase.
  • AlphaCentric Advisors's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $2.13M.
  • AlphaCentric Advisors fully exited UroGen Pharma in Q2 2024, selling an estimated $2.16M.
  • AlphaCentric Advisors's ten largest holdings make up 25% of its $136M portfolio in Q2 2024.
  • AlphaCentric Advisors opened 34 new positions and closed 45 in Q2 2024.
  • AlphaCentric Advisors's portfolio value fell 18% quarter-over-quarter to $136M.

Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.